



EFFECTIVE DATE: 06|01|2006
POLICY LAST UPDATED: 02|19|2019

OVERVIEW

This policy documents the coverage criteria for Islet Cell Transplants. Autologous islet transplantation, performed in conjunction with pancreatectomy, is proposed to reduce the likelihood of insulin dependent diabetes. Moreover, allogeneic islet cell transplantation is being investigated as a treatment or cure for patients with type 1 diabetes.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Autologous Islet Transplantation:

BlueCHiP for Medicare and Commercial Products

Autologous pancreas islet transplantation is considered medically necessary as an adjunct to a total or near total pancreatectomy in members with chronic pancreatitis. Islet transplantation is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial products in all other situations as the evidence is insufficient to determine the effects of the technology on health outcomes.

Allogeneic Islet Transplantation:

BlueCHiP for Medicare

Allogeneic Pancreatic islet cell transplantation is covered for BlueCHiP for Medicare members only as part of an approved clinical trial. Refer to Related Policy section.

Note: Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

Commercial Products

Allogeneic islet transplantation is considered not medically necessary for the treatment of type 1 diabetes as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement, for applicable not medically necessary/not covered/transplant surgery/experimental/investigational benefits/coverage.

BACKGROUND

Performed in conjunction with pancreatectomy, autologous islet transplantation is proposed to reduce the likelihood of insulin-dependent diabetes. Allogeneic islet cell transplantation is also being investigated as a treatment or cure for patients with type 1 diabetes.

Chronic Pancreatitis

Primary risk factors for chronic pancreatitis include toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive (the TIGAR-O classification system). Patients with chronic pancreatitis may experience intractable pain that can only be relieved with a total or near total pancreatectomy. However, the pain relief must be balanced against the certainty that the patient will be rendered an insulin-dependent diabetic.

Type 1 Diabetes

Glucose control is a challenge for individuals with type 1 diabetes. Failure to prevent disease progression can lead to long-term complications such as retinopathy, neuropathy, nephropathy, and cardiovascular disease

ISLET TRANSPLANTATION

In autologous islet transplantation during the pancreatectomy procedure, islet cells are isolated from the resected pancreas using enzymes, and a suspension of the cells is injected into the portal vein of the patient's liver. Once implanted, the beta cells in these islets begin to make and release insulin.

Allogeneic islet transplantation potentially offers an alternative to whole-organ pancreas transplantation. In the case of allogeneic islet cell transplantation, cells are harvested from a deceased donor's pancreas, processed, and injected into the recipient's portal vein. Up to 3 donor pancreas transplants may be required to achieve insulin independence. However, a limitation of islet transplantation is that 2 or more donor organs are usually required for successful transplantation, although experimentation with single-donor transplantation is occurring. A pancreas that is rejected for whole-organ transplant is typically used for islet transplantation. Therefore, islet transplantation has generally been reserved for patients with frequent and severe metabolic complications who have consistently failed to achieve control with insulin-based management. Allogeneic transplantation may be performed in the radiology department. In 2000, a modified immunosuppression regimen increased the success of allogeneic islet transplantation. This regimen is known as the "Edmonton protocol."

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation title 21, parts 1270 and 1271. Islet cells are included in these regulations.

For individuals with chronic pancreatitis who receive autologous pancreas islet transplantation, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, change in disease status, medication use and treatment-related morbidity. Autologous islet transplants are performed in the context of total or near total pancreatectomies to treat intractable pain for chronic pancreatitis. The procedure appears to significantly decrease the incidence of diabetes after total or near total pancreatectomy in patients with chronic pancreatitis. In addition, this procedure is not associated with serious complications itself and is performed in patients who are already undergoing a pancreatectomy procedure. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with type 1 diabetes who receive allogeneic pancreas islet transplantation, the evidence includes a randomized controlled trial, case series, and systematic reviews. Relevant outcomes are overall survival, change in disease status, medication use, resource utilization, and treatment-related morbidity. Results of a 2018 randomized trial have suggested some reduction in the number of severe hypoglycemic incidence annually, but limited follow-up and other trial limitations reduce the certainty in conclusions drawn. A wide range of insulin independence has been reported in case series. There is conflicting evidence whether allogeneic islet transplantation reduces long-term diabetic complications. Long-term comparative studies are

required to determine the effects of allogeneic islet transplantation in type 1 diabetics. The evidence is insufficient to determine the effects of the technology on health outcomes.

Medicare covers pancreatic islet transplantation in patients with type 1 diabetes participating in a clinical trial sponsored by the National Institutes of Health. Partial pancreatic tissue transplantation or islet transplantation performed outside a clinical trial are not.

CODING

BlueCHiP for Medicare

The following code is covered with a diagnosis of chronic pancreatitis:

48160 Pancreatectomy, total or subtotal, with autologous transplantation of pancreas or pancreatic islet cells

ICD-10 Diagnosis Code: **K86.1** Other Chronic Pancreatitis

The following code is reported for pancreatic islet cell transplantation and laparoscopy:

48999 Unlisted procedure, pancreas

The HCPCS codes listed below are allowed for BlueCHiP for Medicare as part of a CMS approved clinical study. Claims for services rendered as part of a CMS approved clinical study must be billed with an appropriate modifier:

Modifier Q0 – Investigational clinical service provided in a clinical research study that is in an approved research study (BlueCHiP for Medicare claims filed without the Q0 modifier will deny as not covered)

Modifier Q1 – Routine clinical service provided in a clinical research study that is in an approved clinical research study

G0341 Percutaneous islet cell transplant, includes portal vein catheterization and infusion

G0342 Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion

G0343 Laparotomy for islet cell transplant, includes portal vein catheterization and infusion

Note: If you are treating a BlueCHiP for Medicare member as part of a CMS approved study, please follow the procedures for correct billing and coding of services found in the policy for Clinical Trials BlueCHiP for Medicare.

Note: For HCPCS code S2012: This code is invalid for BlueCHiP for Medicare and the service should be filed with an alternate code.

Commercial Products

The following code is covered with a diagnosis of chronic pancreatitis:

48160 Pancreatectomy, total or subtotal, with autologous transplantation of pancreas or pancreatic islet cells

ICD-10 Diagnosis Code: **K86.1** Other Chronic Pancreatitis

The following code is reported for pancreatic islet cell transplantation and laparoscopy:

48999 Unlisted procedure, pancreas

The following codes are considered not medically necessary:

G0341 Percutaneous islet cell transplant, includes portal vein catheterization and infusion

G0342 Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion

G0343 Laparotomy for islet cell transplant, includes portal vein catheterization and infusion

S2102 Islet cell tissue transplant from pancreas, allogeneic

RELATED POLICIES

Clinical Trials BlueCHiP for Medicare

BlueCHiP for Medicare National and Local Coverage Determinations

NonReimbursable Health Service Codes

PUBLISHED

Provider Update, May 2019
Provider Update, Nov. /Dec. 2018
Provider Update, November 2017
Provider Update, January 2017
Provider Update, November 2014
Provider Update, April 2015
Provider Update, September 2013
Provider Update, September 2012

REFERENCES:

1. National Institute of Diabetes and Digestive and Kidney Diseases. Pancreatic Islet Transplantation. 2013; <https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments/pancreatic-islet-transplantation>. Accessed July 31, 2018.
2. Wu Q, Zhang M, Qin Y, et al. Systematic review and meta-analysis of islet autotransplantation after total pancreatectomy in chronic pancreatitis patients. *Endocr J*. Mar 30 2015;62(3):227-234. PMID 25735805
3. Dong M, Parsaik AK, Erwin PJ, et al. Systematic review and meta-analysis: islet autotransplantation after pancreatectomy for minimizing diabetes. *Clin Endocrinol (Oxf)*. Dec 2011;75(6):771-779. PMID 21605156
4. Wilson GC, Sutton JM, Abbott DE, et al. Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? *Ann Surg*. Oct 2014;260(4):659-665; discussion 665-657. PMID 25203883
5. Chinnakotla S, Radosevich DM, Dunn TB, et al. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg*. Apr 2014;218(4):530-543. PMID 24655839
6. Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. *J Am Coll Surg*. Apr 2012;214(4):409-424. PMID 22397977
7. Food and Drug Administration (FDA). Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. 2009; <https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM182441.pdf>. Accessed July 30, 2018.
8. Health Quality Ontario. Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review. *Ont Health Technol Assess Ser*. Dec 2015;15(16):1-84. PMID 26644812
9. Piper M, Seidenfeld J, Aronson N. Islet transplantation in patients with type 1 diabetes mellitus. *Evid Rep Technol Assess (Summ)*. Jul 2004(98):1-6. PMID 15366369
10. Lablanche S, Vantuyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol*. May 15 2018 6(7):527-537. PMID 29776895
11. Alejandro R, Barton FB, Hering BJ, et al. 2008 Update from the Collaborative Islet Transplant Registry. *Transplantation*. Dec 27 2008;86(12):1783-1788. PMID 19104422
12. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. *Diabetes Care*. Jul 2012;35(7):1436-1445. PMID 22723582
13. Thompson DM, Meloche M, Ao Z, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. *Transplantation*. Feb 15 2011;91(3):373-378. PMID 21258272
14. Caiazzo R, Vantuyghem MC, Raverdi V, et al. Impact of procedure-related complications on long-term islet transplantation outcome. *Transplantation*. May 2015;99(5):979-984. PMID 25393157
15. O'Connell PJ, Holmes-Walker DJ, Goodman D, et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. *Am J Transplant*. Jul 2013;13(7):1850-1858. PMID 23668890
16. Rickels MR, Kong SM, Fuller C, et al. Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes. *J Clin Endocrinol Metab*. Nov 2013;98(11):E1780-1785. PMID 24085506

17. National Institute for Health and Care Excellence (NICE). Allogenic pancreatic islet cell transplantation for type 1 diabetes mellitus [IPG257]. 2008; <https://www.nice.org.uk/Guidance/IPG257>. Accessed July 30, 2018.

18. National Institute for Health and Care Excellence (NICE). Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy [IPG274]. 2008; <https://www.nice.org.uk/Guidance/IPG274>. Accessed July 30, 2018.

19. Centers for Medicare & Medicaid. National Coverage Determination (NCD) for ISLET CELL Transplantation in the Context of a Clinical Trial (260.3.1). 2004; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=286&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=islet+cell&KeywordLookUp=Title&KeywordSearchType=And&bc=gAAAABAAAA&>. Accessed July 30, 2018.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

